Condition: Rectal Cancer · Rectal Tumor · Rectal/Anal · Sponsor: Colospan Ltd.
A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.
This description comes directly from the study's public registry record.
Boaz Assaf · +972-9-7672518 · boaz@colospan.com
Shelly Sharon, MSc · Shelly@colospan.com
Always discuss trial participation with your own doctor first.
| University of California Irvine | Irvine, California, United States | Active Not Recruiting |
| Kaiser Permanente San Diego medical Center | San Diego, California, United States | Recruiting |
| Colorado University Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Henry Ford Health System | Detroit, Michigan, United States | Recruiting |
| Lifespan & Brown Surgical Associates | Providence, Rhode Island, United States | Active Not Recruiting |
| University of Utah Health | Salt Lake City, Utah, United States | Active Not Recruiting |
| Asklepios | Hamburg, Germany | Recruiting |
| Soroka University Medical Center | Beersheba, Israel | Recruiting |
| Humanitas Research Hospital | Milan, Lombardy, Italy | Recruiting |
| CHUV | Lausanne, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04184973